CKD AnemiaREDCURENCT07346547
REDCURE Registry for Chronic Kidney Disease (CKD) Anemia
An observational study of CKD Anemia, run by Nabiqasim Industries (Pvt) Ltd.
Trial summary
A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- CKD Anemia
- What is being tested?
- Daprodustat
- How many people
- 384 participants
- Where
- No sites listed yet
- Study dates
- 30 Jan 2026to 31 May 2027
- How long will I take part?
- 3 Months
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients with Chronic Kidney Disease (CKD) anemia requiring anemia treatment
Who may be able to join
- Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
- Patients on hemodialysis (HD) or peritoneal dialysis (PD)
- Post-kidney transplant patients with CKD 3. Receiving or initiating Daprodustat therapy (new start or switch therapy) 4. CKD stages 3-5, dialysis patients (HD/PD), or post-transplant with CKD anemia 5. Able and willing to provide informed consent
Who cannot join
- Acute Kidney Injury (AKI) without underlying chronicity
- Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
- Refusal or inability to provide consent
- Current enrollment in an interventional trial that restricts real-world data collection
- Life expectancy < 3 months, where follow-up is not feasible
- Known contraindications to Daprodustat as per local prescribing information
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)
A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat
- Conditions
- CKD Anemia
- Being tested
- Daprodustat
- Keywords
- Daprodustat, oral HIF PHI, CKD anemia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
DaprodustatDrug
Hypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug
| Study group | Role | What they receive |
|---|---|---|
| Daprodustat arm for CKD anemia patients | Daprodustat arm for CKD anemia patients Receives: Drug: Daprodustat |
What is being measured
The primary outcome is the main question the study is designed to answer.
Serum hemoglobin levels
Hemoglobin response to therapy
Measured: 3 months
Secondary outcomes (1)
Frequency of MACE ( Major Adverse Cardiovascular Events)
MACE events:
- Unstable angina requiring hospitalization
- Non-fatal MI
- Non-fatal stroke
- Cardiovascular death
- Other adverse events
- Hospitalization episodes . Mortality
- Optional patient-reported outcomes (fatigue, functional status)
Measured: 3 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted16 Jan 2026
- Study start30 Jan 2026 (estimated)
- Primary completion30 Jan 2027 (estimated)
- Study completion31 May 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for CKD AnemiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 384 participants (estimated)
- Target duration
- 3 Months
Sponsor and investigators
- Lead sponsor
- Nabiqasim Industries (Pvt) Ltd
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07346547
- Sponsor's protocol ID
- NQ/DP/JES/Reg-006
- Acronym
- REDCURE
- Status last verified
- Jan 2026
- First submitted
- 8 Jan 2026
- Last updated
- 20 Jan 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 20 Jan 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Registry of Daprodustat in Chronic Kidney Disease (CKD) Anemia for Understanding Real-World Evidence (REDCURE)
- ClinicalTrials.gov ID
- NCT07346547
- Acronym / sponsor ID
- REDCURE / NQ/DP/JES/Reg-006
- Conditions
- CKD Anemia
- Keywords
- Daprodustat, oral HIF PHI, CKD anemia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 384 participants (estimated)
- Lead sponsor
- Nabiqasim Industries (Pvt) LtdIndustry (pharma, biotech, devices)
- Study start
- 30 Jan 2026 (estimated)
- Primary completion
- 30 Jan 2027 (estimated)
- Study completion
- 31 May 2027 (estimated)
- First posted
- 16 Jan 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
A local registry on CKD-associated anemia aims to provide real-world insights into disease burden, treatment patterns, and outcomes at the national level. It helps capture variations in anemia severity with CKD stages, therapeutic practices and their response. It also supports evidence-based decision-making, identifies gaps in care, and informs locally relevant guidelines and policy planning to improve patient outcomes with oral novel therapy i.e. daprodustat
Study design
- Observational model
- Case only
- Time perspective
- Prospective
- Target follow-up
- 3 Months
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Daprodustat arm for CKD anemia patients | – | Drug: DaprodustatDaprodustat arm for CKD anemia patients |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients with Chronic Kidney Disease (CKD) anemia requiring anemia treatment
Key inclusion criteria (3 listed)
- Adults ≥ 18 years 2. Diagnosed CKD-associated anemia Chronic Kidney Disease (CKD) diagnosed as per KDIGO criteria, including: CKD stages G3-G5 (based on eGFR)
Key exclusion criteria (6 listed)
- Acute Kidney Injury (AKI) without underlying chronicity
- Hematologic disorders not related to CKD (e.g hemolytic anemia, aplastic anemia)
- Refusal or inability to provide consent
- Current enrollment in an interventional trial that restricts real-world data collection
- Life expectancy < 3 months, where follow-up is not feasible
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| DaprodustatHypoxia Inducible Factor (HIF) Prolyl Hydroxylase Inhibitor (PHI) drug | Drug | Daprodustat arm for CKD anemia patients |
Primary outcome
Serum hemoglobin levels
Time frame: 3 months
Hemoglobin response to therapy
1 secondary outcome
Frequency of MACE ( Major Adverse Cardiovascular Events)
Time frame: 3 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 20 Jan 2026.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Related InfoLink provided by the sponsor.
- Individual participant dataSharing planned: No
Related trials for CKD Anemia
Not yet recruitingPhase 1
Study of CTX001 in Adults With Anemia Due to Non-Dialysis-Dependent Chronic Kidney Disease
Chronic Kidney Disease, Anemia
RecruitingObservational study
Nutritional Status in Patients With Chronic Kidney Disease Receiving 7.2% Amino Acids During Hemodialysis
Malnutitrion, Chronic Kidney Disease on Hemodialysis
Active, not recruitingPhase 3
A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease
Chronic Kidney Disease, Renal Anemia
RecruitingPhase 2
A Study of Luspatercept in People With Anemia
Anemia, Chronic Kidney Disease
Not yet recruitingObservational study
ESA Hyporesponsiveness in Hemodialysis Patients
Chronic Kidney Disease (CKD), Hemodialysis Complication
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Questions about this trial
What is this clinical trial studying?
An observational study of CKD Anemia, run by Nabiqasim Industries (Pvt) Ltd.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 20 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hussain Abidi (+923322583236, NQmedicalaffairs@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Serum hemoglobin levels (time frame: 3 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Jan 2026.